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Abstract
Alzheimer’s disease (AD) is characterized by tau tangles and amyloid-β (Aβ) peptide aggregates
amyloids in the brain, specifically in the hippocampus. Aβ plaques are known to form primarily
in the extracellular space around neuronal cells, interfering with synaptic transmission. The
aggregation of Aβ in the hippocampus is associated with a decline in hippocampally-mediated
cognitive abilities, which is a symptom of AD. AD has a strong correlation to type 2 diabetes
mellitus (T2DM), which is defined by hyperinsulinemia and dysregulated glucose metabolism. It
has been shown that insulin plays a role in both memory and learning in the hippocampus. The
simultaneous elevation in insulin and Aβ suggests a connection between the molecular effectors
of both T2DM and AD, insulin and Aβ (monomeric, oligomeric and fibril), respectively.
Moreover, both zinc and calcium are required for the stabilization of insulin and AD patients show
signs of both zinc and calcium dysregulation. Thus, I propose that destabilization of insulin
facilitates Aβ oligomerization. To investigate the relationship between Aβ and insulin, I varied
concentrations of Aβ, insulin, zinc, calcium and glucose and observed amyloid formation by
performing dot blot immunoassays. I have found that at low concentrations of calcium and zinc
and high concentrations of glucose, increased formation of Aβ oligomers were observed. I discuss
future experimentation to further characterize these complexes on the molecular level.
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Background
Alzheimer’s disease (AD) is a devastating incurable neurological disorder that is seen to
affect more than 5.4 million people in the United States, with a vast majority being over the age
of 65. Today, someone develops AD on average every 66 seconds with forecasted estimates to
reach 13.8 million in the United States by 2050. AD is the 6th leading cause of death in the
United States, killing more than breast and prostate cancers combined.1 AD is characterized by
intracellular tau tangles and extracellular aggregation of amyloid-β (Aβ) peptides in the brain,
primarily in the hippocampus. The hippocampus is located in the brains medial temporal lobe,
and is known primarily for its association in memory formation, emotion, and spatial
navigation.2 Aβ peptides congregate in the extracellular space between neurons, causing a
decline in synaptic transmission, in turn decreasing hippocampally-mediated cognitive abilities
which is symptomatically seen in AD. AD is the leading form of senile dementia, accounting for
roughly 80 percent of cases.3
There are two main hypotheses, the tau hypothesis and the amyloid hypothesis, that
provide some possible pathways and framework for this amyloidogenic disease, but the
pathology is still not well understood. Rather, a large variety of mechanisms contribute
simultaneously to the disease, causing its complexity. The first major breakthrough in
understanding the neuropathology of AD came from Glenner and Wong (1984), who purified Aβ
from senile plaques (SP) associated with the disease.4 Aβ is a 36-43 residue protein that is
derived from the amyloid-β precursor protein (APP) after it is cleaved by β-secretase and γsecretase. Aβ40 and Aβ42 are the most common isoforms found in SP, with Aβ42 being more
fibrillogenic and neurotoxic,5 and are therefore the main focus of AD research. The insoluble Aβ
plaques are mainly composed of misfolded Aβ proteins, although a SP has been observed to
5

contain up to 488 unique proteins.6 Aβ is considered an intrinsically unstructured protein due to
its ability to take on many different conformations in solution, allowing for promiscuous
interactions with many substrates.7 There are three conformation forms for Aβ: monomeric,
oligomeric and fibrillar. Soluble oligomeric Aβ is reputed to be the most neurotoxic form,8 and is
seen to be incorporated in multiple facets of the dementia aspect of the disease.
Another disease that has reached epidemic levels in the United States is Type II Diabetes
Mellitus (T2DM) which is an incurable metabolic disorder characterized by dysfunctional insulin
signaling. Insulin is a hormone that regulates blood sugar levels by promoting the uptake of
glucose into cells. In a T2DM patient, the body has an abnormally high resistance to insulin, and
the beta cells of the islets of Langerhans in the pancreas cannot produce enough insulin to
compensate for the inadequate signaling. This results in heightened blood glucose levels, or
hyperglycemia. The insulin resistance also leads to hyperinsulinemia, or excess insulin in the
blood.9 Though insulin has been established as a peripheral glucose regulator, studies have
suggested that responsive insulin receptors (IR) are expressed in the central nervous system,
including the hippocampus.10 Additionally, it is seen that insulin plays a role in hippocampallymediated tasks, such as memory.11
Many studies suggest that T2DM patients are at an increased risk for AD,12 and AD has
been coined the term “Type 3 diabetes” due to the commonality of insulin dysregulation and
resistance.13 Clinical studies have supported the strong correlation between T2DM and AD via
hyperinsulinemia and insulin resistance.14 These characteristics, along with hyperglycemia,
connect T2DM and AD through common symptoms such as inflammation, oxidative stress and
cognitive impairment, or directly through Aβ and tau.15-17 The primary molecular effectors of
both AD and T2DM, Aβ and insulin, respectively, are also linked. For instance, insulin
6

encourages Aβ production by stimulating the activity of γ-secretase in Aβ cleavage and by the
release of intraneuronal Aβ.18,19 Insulin was also found to promote APP metabolism.20
Additionally, insulin and Aβ are degraded by the same insulin-degrading enzyme (IDE),
suggesting that hyperinsulinemia may elevate Aβ through competitive degradation.21
Conversely, Aβ also functions in insulin’s regulation and pathways. Aβ competitively
antagonizes insulin by binding to IRs, which further exacerbates insulin resistance by blocking
the signal transduction of the receptor.22
Aβ and insulin are both
amyloidogenic proteins that share
similar structural motifs, and can
aggregate with one another.23,24
Due to their similarities and
connections via IDE, APP and
overall integration within each
Figure 1: Potential model for Aβ seeding via destabilized insulin
aggregation.

other's regulation,18-22 it is possible
that insulin is related to the

accumulation of Aβ plaques. It is also not unreasonable for a third-party substrate to be involved
in this connection. This is further supported by the multitude of molecular components found in a
SP.6 One of three additional components that is explored is zinc. Zinc is an essential metal for
homeostasis and physiologically found in cationic form.25 Zinc is integrated throughout the body,
playing roles in prosthetic groups, protein structure, co-enzyme, signaling, etc.25,26 Zinc ions are
a cofactor for the hexamerization of insulin. Usually two ions are needed, otherwise insulin will
typically remain as a dimer or tetramer.27 Disputably, dysfunctional homeostasis of specific
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transition metals, one of which being zinc, are believed to play a role in the pathogenesis of
AD.28,29 In more recent research, this zinc AD pathology model involving increased localization
of zinc in cortical grey matter and pathological lesions has been supported. The increased
localized zinc levels are accompanied with a decrease in systemic and cellular zinc levels.29
Zinc’s association with AD, along with its strong association with insulin and IRs29 followed by
the cascading effect of insulin resistance and hyperinsulinemia, lead to a more supportive need
for the exploration of zinc in this context.
An additional constituent that is explored is calcium. Calcium is an essential metal found
in all cells in the body, playing roles from cell signaling to muscle contraction and hormone
regulation.30,31 Like zinc, calcium is also involved in insulin hexamer assembly, but plays a much
larger role in insulin stabilization.32 Destabilized insulin is more likely to take the monomeric or
dimeric form, and is more amyloidogenic.33 Even partial destabilized insulin is enough for its
aggregation.34 Small insulin aggregates act as nucleation sites for further growth.33 This initial
seed of insulin amyloid can hypothetically interact with Aβ, creating an alternative pathway for
the initiation of Aβ plagues. Additionally, calcium dysregulation is correlated to AD via the
calcium hypothesis.35,36 This hypothesis explains calcium ion signaling dysregulation leading to
neurodegeneration and apoptosis via the amyloidogenic Aβ pathway.35 In brief, this hypothesis
accuses Aβ oligomers for increasing the concentration of calcium ions pumped into the
endoplasmic reticulum creating a cascade that ultimately ends with the release of internal
calcium storages leading to calcium dyshomeostasis.35 The crux of this hypothesis revolved
around the possibility of Aβ40 and Aβ42 peptides forming an ion channel that incorporates into
the bilayer, allowing an influx of calcium ions.37
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The third constituent under exploration is glucose. The human brain’s main energy
source is glucose and it accounts for roughly 20% of total glucose-derived energy consumption
in the body. Glucose’s main metabolite is ATP, which is used for neuronal function,
maintenance, neurotransmitter production and other processes.38 Dysglycemia is a standard
characteristic seen in both T2DM and AD, with hyperglycemia being a major connection
between the two diseases as previously discussed. Additionally, research has shown in rat
models that extracellular glucose in the hippocampus is depleted during cognitive activity
(spatial working memory), and that task performance is enhanced by the administration of
exogenous glucose.39 Furthermore, it is also reported that hyperglycemia is associated with a
decline in cognitive performance in diabetic patients.40 This reinforces the importance of tight
glucose regulation and supports the association of cognitive impairment during dysglycemia as
seen in both T2DM and AD. Glucose is also regulated by insulin as previously mentioned. The
necessity of glucose for proper brain function along with the strong association of glucose
dysregulation during T2DM and AD diseased states are just some of the reasoning for the
exploration of glucose in its interactions with Aβ plaque formation.
Materials and Methods
Dot blot
The dot blot technique is used to determine the presence of monomeric/oligomeric/fibril
Aβ. Dot blotting is usually done by spotting small samples volumes onto a nitrocellulose
membrane in a grid like fashion. Marks are made in pencil at the top and side of the membrane to
pinpoint spot locations. Each sample is normalized by the present protein mass concentrations to
allow uniform signaling. Two microliters of a sample are spotted onto the membrane at the
corresponding location. Spots are blotted in succession for each sample set, each being a dilution
9

of 1:2 from the preceding spot. Multiple sample sets can be spotted on one membrane sheet. As
an improvement for manual dot blotting, a dot blot apparatus (e.g. by Bio-Rad) can be used,
which allows for up to 96 samples in a 8x12 fashion, each with volumes between 200 and 500
μL to be spotted with the help of a vacuum.

1
2
3
4
5
6
7
8
9
10

Aβ (pg/mL)
Insulin (pg/L)
Calcium (mM) Zinc (mg/L)
Glucose (mM)
1500
0.349
0.07
0.02
0.125
1500
0.349
0.07
0.02
12.5
50000
349
7
2
0.125
50000
349
7
2
12.5
1500
349
0.07
0.02
12.5
50000
349
0.07
0.02
12.5
1500
349
7
0.02
12.5
50000
349
7
0.02
12.5
50000
349
0.07
0.02
12.5
50000
349
0.07
2
12.5

Table 1: Five different sets with varying concentrations of Aβ, insulin, calcium, zinc, and glucose were tested
by dot blotting.

Two sheets of filter paper, which were dampened with DI water, and a nitrocellulose
membrane with a pore size of 0.2 μm (Amersham Protran 0.2 NC, GE Healthcare Life Sciences,
prod. code 10600004) were cut (7.5cm x 11.5cm) and assembled in the dot blot apparatus. Serial
dilutions of the stock solutions (table 1) were initially prepared in PBS, but then later only in 150
mM sodium chloride (Sigma) and 50 mM Tris-HCl, pH 7.5 (Sigma) and applied to the
membrane by using one master stock solution and varying the volumes applied to the membrane.
The highest concentration was achieved by spotting 6 mL of the solution onto the membrane,
then 5 mL, 4 mL, etc. This was done with successive applications of 500µL, after each was fully
passed through with the help of the full vacuum appendage and valve. The membrane was cut
into four strips, destined for the respectively labeled antibody or loading control.
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Aβ protein fragment 1-42 (Sigma, cat. 107761-42-2), zinc-free insulin (Apidra insulin
glulisine 100 U/mL), calcium chloride (Sigma), zinc chloride (Sigma) and D-(+) glucose (Sigma)
were all used in their respective dosages in the creation of a master stock solution (100 mL) for
each respective set seen in table 1. The dose values for each constituent are based off of
estimated physiological levels pulled from the literature, with a deviation low (blue) and high
(red) from these levels for each respectively. In attempt to create conditions closely mocking
those seen physiologically, cerebrospinal fluid (CSF) or even mouse extracellular fluid (ECF)
values were used, since no human brain ECF values are seen to be reported. Aβ CSF values
fluctuate greatly in literature, and the correlation between increased, decreased or unchanged Aβ
levels in AD patients compared to healthy controls is seemingly unestablished. Nonetheless,
Aβ42 CSF levels were seen to reside at ~500 pg/mL.41,42 This value was thus used as a baseline
for Aβ concentration, but due to the minimum sensitivity of the dot blot assay, the low
concentrations used are seen to be three times of the estimated baseline values. The loose
knowledge between CSF Aβ levels and those actually seen in the human brain allow for this
small deviation. Additionally, it would be expected that in an AD diseased state, the Aβ levels,
especially those around SPs, would be at a much higher concentration. From this, and the mere
exploration of Aβ in these experiments leads to the deviation of the high Aβ value of 50,000
pg/mL or 100x greater of the previously established estimated baseline. Likewise, this was done
for insulin, with an estimated baseline or roughly 3 pg/L43, with 100x deviations for both high
and low concentrations. The exact values of 0.349 and 349 pg/L (low and high respectively)
were used due to the simplicity of dilutions found from the stock Insulin (Apidra). Additionally,
calcium concentrations of 0.7 mM44 are reported in mouse hippocampus ECF; zinc
concentrations of roughly 0.2 mg/L45 are reported in CSF levels in AD patients; and glucose ECF
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concentrations are reported to be 1.25 mM44. These concentrations were used as rough estimates
to mock physiological concentrations as expectedly seen in a T2DM/AD diseased brain. These
values once again, were used as a baseline, and both high and low concentrations were
established from these values. The magnitude for deviation for calcium, zinc and glucose were
10x that from baseline, opposed to the 100x for Aβ and insulin due the increased interest in the
involvement and interactions between the proteins. Lastly, though not recorded, it should be
known that there are also chloride ions in each of the solutions due to the use of CaCl2 and
ZnCl2.
Each solution set as seen in table 1 was incubated at 37°C for 1 hour, followed by a 20minute cool off period, after creation. The spotting was done in sets of two (1&2, 3&4, etc.) as
blotting immediately followed.
The Aβ stock was sonicated in a cold water bath for 1 minute after being suspended in 10
mM sodium hydroxide solution and later frozen at -20°C for storage. All other reagents used
were stored as recommended.
Loading control
One strip was rinsed with Milli-Q water, then stained with approximately 20 mL of Silver
Stain (40% Sodium Citrate, 20% Iron (II) Sulfate-heptahydrate, 20% Silver nitrate weight per
volume solutions mixed in a 90:5:4:1 Water: Sodium citrate: Iron sulfate: Silver nitrate ratio).
This loading control sample was incubated on a rocker at room temperature (RT) for 30 minutes,
then rinsed with DI water.
Immunoblot detection

12

The three-remaining membranes were blocked for 1 hour at room temperature with 10-15
mL of blocking buffer (10% milk-PBST [PBS + 0.1% Tween20]). Following three 15-minute
washes with DI water, the membranes were incubated with a 1:5000 dilution of LOC antibody in
PBST (host rabbit, cat. AB2287, EMD Millipore), a 1:2000 dilution 6E10 antibody in 5% milkPBST (host mouse, cat. 803001, Jackson ImmunoResearch Inc.), or a 1:1000 dilution of A11
antibody in 5% milk-PBST (host rabbit, cat. AHB0052, ThermoFisher). Incubation in primary
antibody was done overnight at 4°C on a nutator. Following incubation in primary antibody,
each membrane was washed four times with PBST for 10 minutes at RT. Anti-rabbit HRP or
anti-mouse HRP secondary antibodies were diluted 1:1000 in PBST and 1:10000 in 5% milkPBST, respectively. Membranes were then incubated on a rocker in the appropriate secondary
antibody at room temperature for 1 hour. Following three washes with PBST standard
chemiluminescence detection was performed using a Bio-Rad Chemidoc XRS+ instrument.
Exposure times and signal intensities were chosen to maximize image quality (typically between
30s-120s).
Results
While the volume that can be spotted onto a
membrane via traditional dot-blotting is limited to volumes
of up to 10 μL or less, a dot blot apparatus (e.g. by Bio-Rad)
allows for spotting of up to 96 samples with volumes of up
to 500 μL with the help of a vacuum. To use physiological
Figure 2: Antibody control test. 2
μL of diluted 6E10, LOC and A11
antibodies were spotted straight onto
the nitrocellulose membrane and
incubated with the appropriate
secondary antibody prior to imaging.

concentrations of protein samples, I first established a
protocol to ensure that volumes of up to 6 mL can be applied
to the nitrocellulose membrane.
13

Prior to testing the proposed model (figure 1), antibody activity (figure 2) and specificity
(figures 3 and 5) were tested in several control experiments. To ensure that all antibodies can be
used for immunoblotting, 2 μL of 6E10, LOC and A11 primary antibodies were spotted in their
respective working dilutions and detected with their corresponding secondary antibodies by
immunoblotting. The LOC and A11 primary antibodies are detected with HRP-conjugated antirabbit IgG secondary antibody, while only the 6E10 primary antibody
is specifically detected by HRP-conjugated mouse IgG secondary
antibody (Figure 2). Furthermore, the signal from the LOC antibody
appears to be stronger than the A11 and 6E10 signal. This is not
concerning since this test was merely to show that the antibody is
active. Generally, signal strengths can vary greatly based off
differences in exposure times, changes in binding affinities to the
nitrocellulose membrane due to the presence/absence of the
recognizable protein, or differences in antibodies’ respective working
Figure 3: The A11
antibody minimally
cross-reacts with insulin.
349 pg/L (insulin high)
and 0.349 pg/L (insulin
low) were serially diluted
and detected using the
A11 antibody.

dilutions.
Since Aβ and insulin are both potentially amylogenic proteins,
the A11 antibody, which recognizes amino acid sequence-independent
oligomers, may potentially cross-react and recognize insulin oligomers

in addition to the Aβ oligomers. In the A11 antibody reference sheet, it is mentioned that A11
antibody recognizes other oligomeric species, one of which being human insulin. To determine if
any oligomeric insulin present contributes to a background signal, a serial dilutions of high (349
pg/L) and low (0.349 pg/L) insulin were spotted on a nitrocellulose membrane and an
immunoassay with the A11 antibody was performed (Figure 3). While the A11 antibody does
14

detect some insulin signal, the low signal-to-noise ratio indicated that the levels of insulin has to
be increased far beyond the levels used here to significantly impact the observed A11 signals.
I then tested how the concentration of glucose impacts Aβ
detection. This initial experiment (figure 4) revealed that an
increase in glucose concentration (same conditions as seen in
Table 1, sets 1 and 2 [in PBS not NaCl Tris-HCl buffer]) resulted
in increased binding and detection of Aβ with the LOC antibody.
In attempt to potentially mock a diseased state of hyperglycemia
and with the results seen from figure 4, high glucose conditions
were used in most of the dot blot assays.
I confirmed the conformational form of Aβ detected from
each of the three different antibodies that are used in the
immunoassays. The antibody A11 should detect only oligomeric

Figure 4: Increased levels of
glucose facilitate binding and
detection of Aβ with LOC
antibody. Serial dilutions of
solutions with low
concentrations of Aβ, insulin,
calcium and zinc in PBS, but
varying concentrations of
glucose were spotted and
detected with LOC.

Aβ and minimally cross-reacts with insulin (figure 3). The LOC antibody has been described to
mainly detect fibrils of Aβ and non-specifically detect monomeric Aβ but to a much lesser
extent. The 6E10 antibody should detect all conformational forms of Aβ. The addition of 1%
SDS followed by a 5-minute boil will cause Aβ to become monomeric.46 In contrast, oligomeric
Aβ was formed by incubating Aβ in PBS for 4 days at room temperature46 (RT) or 37°C. Next,
serial dilutions of monomeric and oligomeric Aβ (both RT and 37°C samples) were tested at
starting concentrations of 50000 pg/mL (high) or 1500 pg/mL (low) with all three primary
antibodies. Surprisingly, only high concentrations of monomeric Aβ were robust enough for
detection by the 6E10 antibody at a low (30s) exposure time, while the lower concentrations
were only weakly detected with a long (120s) exposure time (figure 5, left panel). As expected,
15

although the LOC antibody detects monomeric Aβ, the signal is weaker compared to the 6E10
signal (figure 5, middle panel), and the A11 antibody does not detect monomeric Aβ even during
a long exposure (figure 5, right panel).

Figure 5: Detection of monomeric and oligomeric Aβ with 6E10, LOC and A11 antibodies.
Serial dilutions of 50000 pg/mL (high) and 1500 pg/mL (low) Aβ were spotted and immunoblotting
was performed.

Interestingly, the signal for oligomeric Aβ was much stronger in samples incubated at
physiological temperatures (37°C), and all three antibodies detect signals (figure 5). While it was
expected for the A11 antibody to detect oligomeric Aβ, the oligomerization of Aβ was rather
inefficient, leaving monomeric Aβ to be detectable by the LOC antibody. Because the LOC
antibody has a lower affinity for monomeric Aβ, the signal intensity for the LOC antibody is
decreased compared to the 6E10 antibody. This comparatively lower signal intensity supports the
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rational that the Aβ is still monomeric and not fibril, where if it were fibril, you would expect to
see a stronger signal from LOC. Overall, these results confirm the properties described for these
antibodies.
Once I had established the antibody
properties, I performed the experiments
described in table 1. Because my earlier
experiments indicated that glucose might
increase Aβ binding potentially due to
crowding, I tested whether higher
concentrations of glucose also facilitate Aβ
oligomerization. At low concentrations of Aβ,
insulin, calcium and zinc, glucose does not

Figure 6: Low concentrations of glucose do not appear to
affect Aβ oligomerization at low concentrations of Aβ
and insulin. A11 detects oligomeric Aβ, LOC detects fibrils
and monomeric Aβ and 6E10 detects total Aβ.

appear to alter Aβ oligomerization
(figure 6, sets 1 and 2). At high
concentrations of Aβ, insulin,
calcium and zinc, when comparing
high concentrations of glucose to
low concentrations, the A11
antibody detects oligomerized Aβ at
lower dilution steps in high glucose
Figure 7: Increased glucose concentrations meekly
facilitates some Aβ oligomerization at high
concentrations of Aβ and insulin. A. A11 detects
more oligomeric Aβ at higher concentrations of
glucose. B. Quantification of immunoblot. A11 values
were expressed as a percentage of total signal (6E10).

concentrations (figure 7, sets 3 and
4). This indicates that high glucose
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concentrations meekly facilitate Aβ oligomerization.
Because destabilized insulin has been suggested to form a seed for Aβ to oligomerize,
and calcium plays a large role in insulin stabilization, I

Figure 8: Low concentrations of calcium facilitate some Aβ oligomerization. Low (1500 pg/mL, sets 5 and 7)
and high (50000 pg/ml, sets 6 and 8) concentrations of Aβ were tested in the presence of 349 pg/L insulin, 0.02
mg/L zinc, 12.5 mM glucose and varying concentrations of calcium. A. 0.07 mM calcium B. 7 mM calcium.

next tested the effect of varying calcium concentration on Aβ oligomerization. At low
calcium concentrations A11 detects Aβ at lower dilution steps and with a stronger signal in both
low Aβ and zinc, high insulin and glucose (figure 8, compare panels A and B and set 5 and 7),
and in high Aβ, insulin and glucose, low zinc conditions (figure 8, compare panels A and B and
sets 6 and 8). This indicates that in lower calcium concentrations, destabilized insulin may
indeed form, causing Aβ to aggregate and oligomerize. Interestingly, while the 6E10 antibodies
shows similar detection with varying calcium concentrations, the signal detected by the LOC
antibody is stronger at low calcium concentrations compared to high calcium concentration
(figure 8). This indicates that under low calcium conditions some Aβ fibrils might also be
forming, which do not form at high calcium concentrations.
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Lastly, I tested the effect of varying zinc concentrations has on Aβ oligomerization. Zinc
preferentially stabilizes insulin, so it is expected that Aβ oligomerization is more efficient at low
concentrations of zinc. To shift the equilibrium further, low concentrations of calcium were used.
Overall, good Aβ binding to the membrane was observed under these conditions. In addition, at
low zinc concentrations, oligomerized Aβ has a greater detection at lower dilution steps when
compared to oligomeric Aβ at high
zinc concentrations (figure 9). This
indicates that low zinc concentrations
also facilitates Aβ oligomerization,
albeit to a much lesser extent than low
calcium concentrations.
Interestingly, it appears that
lower concentrations of calcium
overall facilitate better binding of Aβ
to the nitrocellulose membrane

Figure 9: Low concentrations of zinc facilitate some Aβ
oligomerization. High (50000 pg/ml) concentrations of Aβ were
tested in the presence of 349 pg/L insulin, 0.07 mg/L calcium,
12.5 mM glucose and varying concentrations of zinc (0.02 mg/L
and 2 mg/L zinc in set 9 and 10, respectively).

(figures 8, compare panels A and B 6E10, and figure 9), possibly due to the increased
interactions between Aβ and the greater amount of destabilized insulin under low calcium
concentrations. This observation can be confirmed by directly comparing all sets at the same
exposure (figure 10). Aβ signals are strongest in the presence of high Aβ, insulin and glucose
concentrations with low calcium concentrations and either high or low zinc concentrations,
supporting the observation. The effect of varying zinc concentrations seems to have a smaller
effect on overall Aβ binding and Aβ oligomerization (figures 9 and 10).
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Finally, I also tested the suspended Aβ stock solution. Serial dilutions of 50000 pg/mL
(high) and 1500 pg/mL (low) Aβ directly from the suspended stock solution were spotted on a
nitrocellulose membrane and detected with all three primary antibodies. Unpredictably, all three
antibodies detected a signal suggesting that even in the presence of 10 mM sodium hydroxide
some Aβ oligomers have formed (figure 11). This result is quite unexpected and stresses the need
to use other biochemical assays to determine the nature of these Aβ aggregates in the future.
Discussion
In this study, I investigated
the interactions between Aβ and
insulin in various ionic conditions.
To perform these studies with near
physiological concentration of Aβ,
insulin, calcium, zinc and glucose I
first established a high-throughput
variation of the dot blot assay. Using
Bio-Rad’s dot blot apparatus, which
is recommended for usage of
Figure 10: Binding of Aβ to nitrocellulose membrane varies
greatly between samples. All ten sets are directly compared with
each other. Exposures are identical between the sets for each
antibody.

volumes between 200 and 500 μL, I
first optimized the assay conditions
that allowed me to use volumes up

to 6 mL. After testing and overall data analysis and comparisons, I found that Aβ oligomers are
better detected at high concentrations of Aβ, insulin and glucose and low concentrations of
calcium and zinc.

20

The initial glucose comparison tests were
done in PBS. However, because calcium phosphate
and zinc phosphate are insoluble, a buffer containing
150 mM sodium chloride and 50 mM Tris-HCl, pH
7.5 were used in all additional assays. The sodium
concentration in this buffer is close to the
physiological plasma levels of sodium, which vary
between 135 – 145 mmol/L47. More importantly, this
buffer is frequently used for co-immunoprecipitation
experiments, where interactions between proteins are
preserved making this buffer suitable for the assay I

Figure 11: Presence of monomeric and
oligomeric Aβ in the stock solution was
tested by immunoblotting.

established here.
Varying glucose concentrations suggested that glucose improved overall Aβ binding to
the nitrocellulose membrane. This could be due to a crowding effect. Macromolecular crowding
has been shown to affect protein folding and stability in vitro.48,49 It is possible that binding of
Aβ to the nitrocellulose membrane is increased due to effects of molecular crowding on Aβ’s
structure/stability in solutions containing high glucose concentrations. Since it is not
unreasonable for glucose to potentially change the structure of Aβ via these crowding effects, it
is possible that Aβ under these effects, could increase the exposure of specific residues, mainly
residues 15-17 and 34-36. These regions of Aβ are known to be involved in Aβ selfaggregation50 and have been reported to be potential sites of preferential insulin interactions.23
Additionally, the more crowded environment seen in the intra-/extracellular space within the
brain can be somewhat replicated by the increased levels of glucose in the context that these
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higher glucose concentrations provide a higher number of total molecules in the samples.
Although this effect appeared to be minor in later experiments, glucose concentrations were kept
constant at (high) 12.5 mM in subsequent experiments.
I further found that low concentrations of calcium, which is known to destabilize insulin,
facilitated better Aβ binding to the nitrocellulose membrane. This finding is consistent with my
model (figure 1). Although this effect has not yet been described in the literature, it is possible
that destabilized insulin aggregates generally improve binding of Aβ to the nitrocellulose
membrane via increased interactions and increases Aβ oligomerization. While this finding
supports my model, it is not yet known whether the Aβ and insulin bound to the membrane at
low calcium concentrations have formed homo- or heteroligomers, or even interact at all. In
contrast to calcium, the effect of varying zinc concentrations is rather modest; low zinc
concentrations meekly increase Aβ oligomer formation. The weaker effect of zinc when
compared to calcium can be explained when looking at insulin conformations and stabilization.
Generally, the presence of calcium has a greater effect on the stabilization of insulin
monomers/dimers and preventing destabilized aggregates, while zinc effect has a greater
association with insulin hexamerization. This supports the disparity in effect strength between
calcium and zinc.
Since the LOC antibody preferentially detects fibrils, but also monomeric Aβ, data
interpretation is challenging without further experiments. Although the LOC signal correlates
well with the signal obtained with the 6E10 antibody, the signal appears to be weaker, which is
expected for detection of monomeric Aβ (figure 8B). However, it cannot be excluded that some
Aβ could formed fibrils at low concentrations of calcium (figure 10, sets 6, 8 and 10). Further
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support for this hypothesis comes from Aβ detection with the A11 antibody, which shows
increased signal intensities for sets 6 and 10.
To determine antibody specificity towards monomeric, oligomeric and fibril forms of Aβ,
Aβ was treated to obtain monomeric or oligomeric conformation (figure 5). Interestingly,
monomeric Aβ was only weakly detected with the 6E10 antibody, even at a concentration of
50000 pg/mL and long exposure time. The solution of monomeric Aβ contains 1% SDS with the
presumed use of preventing homodimer formation. With protein binding to nitrocellulose via
hydrophobic interactions, the addition of SDS decreased protein hydrophobicity, which likely
reduced the protein binding affinity towards the nitrocellulose membrane. To optimize the assay
and increase binding of monomeric Aβ a nitrocellulose membrane with a pore size of 0.1 μm
could be used in the future. Furthermore, the addition of 20% methanol could also increase
protein binding to the nitrocellulose memebrane.
Detection of oligomeric Aβ revealed a signal for all three antibodies. This indicates that
the oligomerization of Aβ was a rather inefficient reaction, and a mixture of monomeric and
oligomeric Aβ most likely is present in the samples. Interestingly, the LOC antibody required a
higher Aβ threshold detection than the A11 antibody (figure 5). With the LOC antibody having a
lower affinity towards monomeric Aβ, and the A11 antibody recognizing oligomeric Aβ only,
this result suggests that the LOC antibody mainly recognized a large amount of monomeric Aβ
and that the presence of oligomers are also abundant, or that there could be a small amount of
fibril detection which overwhelms any monomeric signal detection from the LOC antibody, in
tandem with a large portion of the sample Aβ being oligomeric. Furthermore, by increasing the
incubation temperature to 37°C all antibodies detected lower thresholds Aβ suggesting that the
formation of Aβ oligomers is a kinetically unfavorable reaction, but by increasing the
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temperature the activation energy required for Aβ oligomerization can be partially overcome. In
future testing, the use of a different Aβ oligomerization protocol would advised. The use of
DMSO and phenol-free F-12 cell culture medium51 may have better oligomeric Aβ results.
Lastly, the antibody test of the Aβ stock surprisingly against expectations revealed that 10
mM sodium hydroxide solution does not prevent the formation of some Aβ oligomers. This
finding and the fact that the LOC antibody detects Aβ fibrils and monomers emphasized the need
to use additional biochemical methods in the future to investigate what Aβ conformations were
detected using the dot blot assay. One possible method to explore the nature of the Aβ
conformations is a modified dot blot assay: Following separation of the Aβ conformations on a
gel filtration column, the different fractions can then be tested using immunoblotting. However
due to the use of near physiological concentrations the loss of material might be too significant to
purify these complexes. As an alternate approach, direct mass spectrometry can be performed on
the complexes. In a top-down mass spectrometry approach the mass of intact proteins and
complexes will be determined.52 Specifically, following electrospray ionization (ESI) of the
liquid sample, the sample composition can be determined with a LTQ-Orbitrap Velos mass
spectrometer.53 Because mass spectrometry is highly sensitive, composition of potential homoand heteromeric Aβ/insulin complexes along with the association of calcium, zinc and/or glucose
can be examined in greatest detail.
Additionally, it would be interesting to investigate the interactions between postincubated destabilized insulin aggregates with monomeric Aβ, or oligomeric Aβ and insulin in
similar ionic conditions as those seen in this experimentation. The resulting interactions under
specific conditions seen here can be somewhat extrapolated and show some insight into ideal in
vivo conditions that promote Aβ oligomerization. For instance, increased Aβ concentrations,
24

hyperinsulinemic and hyperglycemic concentrations are a common characteristic in newly
diabetic patients to late stage AD patients. Under conditions of low calcium and/or zinc
concentrations in the brain, the ability of Aβ oligomerization is optimized, potentially speeding
up the onset of AD pathology.
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